4D Molecular Therapeutics (FDMT) Stock Forecast & Price Target

Compare

409 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

FDMT Analyst Ratings

Moderate Buy

8 Buy

2 Hold

1 Sell

Based on 11 analysts giving stock ratings to

Molecular Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

FDMT Stock 12 Month Forecast

Average Price Target

$26.99

▲(271.76% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for 4D Molecular Therapeutics in the last 3 months. The average price target is $26.99 with a high forecast of $45.00 and a low forecast of $5.50. The average price target represents a 271.76% change from the last price of $7.26.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","46":"$46","12.25":"$12.25","23.5":"$23.5","34.75":"$34.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.99,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$26.99</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,12.25,23.5,34.75,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.42,9.387692307692308,12.355384615384615,15.323076923076924,18.29076923076923,21.25846153846154,24.22615384615385,27.193846153846152,30.161538461538463,33.129230769230766,36.096923076923076,39.06461538461539,42.0323076923077,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.42,8.002307692307692,9.584615384615384,11.166923076923077,12.74923076923077,14.331538461538461,15.913846153846155,17.496153846153845,19.07846153846154,20.660769230769233,22.243076923076924,23.825384615384614,25.407692307692308,{"y":26.99,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.42,6.349230769230769,6.2784615384615385,6.207692307692308,6.136923076923077,6.0661538461538465,5.995384615384616,5.924615384615384,5.8538461538461535,5.783076923076923,5.712307692307692,5.641538461538461,5.570769230769231,{"y":5.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.34,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.19,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.01,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.1,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.59,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.57,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.6,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.99,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.44,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.75,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.15,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.42,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$45.00

Average Price Target$26.99

Lowest Price Target$5.50

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Salveen Richter

Goldman Sachs

$44→$38

Buy

423.42%

Upside

Reiterated

08/12/25

4D Molecular Therapeutics (FDMT) Gets a Buy from Goldman Sachs

Gena Wang

Barclays

$38

Buy

423.42%

Upside

Reiterated

08/12/25

Barclays Remains a Buy on 4D Molecular Therapeutics (FDMT)

Matthew Caufield

H.C. Wainwright

$36

Buy

395.87%

Upside

Reiterated

08/12/25

Buy Rating Affirmed for 4D-150: Promising Phase 2a SPECTRA Trial Results and Market Potential

Mani Foroohar

Leerink Partners

$17→$16

Buy

120.39%

Upside

Reiterated

08/12/25

4D Molecular price target lowered to $16 from $17 at Leerink4D Molecular price target lowered to $16 from $17 at Leerink

Jon Arfstrom

RBC Capital

$26

Buy

258.13%

Upside

Reiterated

08/11/25

RBC Capital Sticks to Their Buy Rating for 4D Molecular Therapeutics (FDMT)

Geulah Livshits

Chardan Capital

$25→$25.4

Buy

249.86%

Upside

Reiterated

08/11/25

Chardan Capital Remains a Buy on 4D Molecular Therapeutics (FDMT)Updating our model for 2Q25 financials leaves our PT at $25.4

Judah Frommer

Morgan Stanley

―

Sell

―

Reiterated

08/11/25

Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (NASDAQ: FDMT), Progyny (NASDAQ: PGNY) and Avadel Pharmaceuticals (NASDAQ: AVDL)

Dex Genotek

TR | OpenAI - 4o

$6.5→$5.5

Hold

-24.24%

Downside

Reiterated

08/05/25

AI Generated ArticleAI Generated Article

Daniel Giraldo

Bank of America Securities

$30

Buy

313.22%

Upside

Reiterated

08/01/25

Promising Potential of 4D-150 in DME and wAMD: Buy Rating Affirmed by Analyst

Jonathan Miller

Evercore ISI

$45

Buy

519.83%

Upside

Reiterated

08/01/25

4D Molecular Therapeutics (FDMT) Gets a Buy from Evercore ISI

Kostas Biliouris

BMO Capital

$10

Hold

37.74%

Upside

Reiterated

07/03/25

PhIII Readout Moved Up by ~6mo, But Overall Outlook Continues to Look Cloudy

Kelly Shi

Jefferies

$51→$40

Buy

450.96%

Upside

Reiterated

02/10/25

4D Molecular Therapeutics (FDMT) PT Lowered to $40 at JefferiesJefferies analyst Nalin Tejavibulya lowered the price target on 4D Molecular Therapeutics (NASDAQ: FDMT) to $40.00 (from $51.00) while maintaining a Buy rating.

Joshua Schimmer

Cantor Fitzgerald

―

Hold

―

Downgraded

09/23/24

4D Molecular downgraded to Neutral from Overweight at Cantor Fitzgerald4D Molecular downgraded to Neutral from Overweight at Cantor Fitzgerald

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Salveen Richter

Goldman Sachs

$44→$38

Buy

423.42%

Upside

Reiterated

08/12/25

4D Molecular Therapeutics (FDMT) Gets a Buy from Goldman Sachs

Gena Wang

Barclays

$38

Buy

423.42%

Upside

Reiterated

08/12/25

Barclays Remains a Buy on 4D Molecular Therapeutics (FDMT)

Matthew Caufield

H.C. Wainwright

$36

Buy

395.87%

Upside

Reiterated

08/12/25

Buy Rating Affirmed for 4D-150: Promising Phase 2a SPECTRA Trial Results and Market Potential

Mani Foroohar

Leerink Partners

$17→$16

Buy

120.39%

Upside

Reiterated

08/12/25

4D Molecular price target lowered to $16 from $17 at Leerink4D Molecular price target lowered to $16 from $17 at Leerink

Jon Arfstrom

RBC Capital

$26

Buy

258.13%

Upside

Reiterated

08/11/25

RBC Capital Sticks to Their Buy Rating for 4D Molecular Therapeutics (FDMT)

Geulah Livshits

Chardan Capital

$25→$25.4

Buy

249.86%

Upside

Reiterated

08/11/25

Chardan Capital Remains a Buy on 4D Molecular Therapeutics (FDMT)Updating our model for 2Q25 financials leaves our PT at $25.4

Judah Frommer

Morgan Stanley

―

Sell

―

Reiterated

08/11/25

Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (NASDAQ: FDMT), Progyny (NASDAQ: PGNY) and Avadel Pharmaceuticals (NASDAQ: AVDL)

Dex Genotek

TR | OpenAI - 4o

$6.5→$5.5

Hold

-24.24%

Downside

Reiterated

08/05/25

AI Generated ArticleAI Generated Article

Daniel Giraldo

Bank of America Securities

$30

Buy

313.22%

Upside

Reiterated

08/01/25

Promising Potential of 4D-150 in DME and wAMD: Buy Rating Affirmed by Analyst

Jonathan Miller

Evercore ISI

$45

Buy

519.83%

Upside

Reiterated

08/01/25

4D Molecular Therapeutics (FDMT) Gets a Buy from Evercore ISI

Kostas Biliouris

BMO Capital

$10

Hold

37.74%

Upside

Reiterated

07/03/25

PhIII Readout Moved Up by ~6mo, But Overall Outlook Continues to Look Cloudy

Kelly Shi

Jefferies

$51→$40

Buy

450.96%

Upside

Reiterated

02/10/25

Joshua Schimmer

Cantor Fitzgerald

―

Hold

―

Downgraded

09/23/24

4D Molecular downgraded to Neutral from Overweight at Cantor Fitzgerald4D Molecular downgraded to Neutral from Overweight at Cantor Fitzgerald

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering 4D Molecular Therapeutics

1 Month

xxx

Success Rate

7/19 ratings generated profit

Average Return

-3.95%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 36.84% of your transactions generating a profit, with an average return of -3.95% per trade.

3 Months

xxx

Success Rate

6/19 ratings generated profit

Average Return

-10.32%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 31.58% of your transactions generating a profit, with an average return of -10.32% per trade.

1 Year

Matthew CaufieldH.C. Wainwright

Success Rate

10/21 ratings generated profit

Average Return

+0.02%

reiterated a buy rating 6 days ago

Copying Matthew Caufield's trades and holding each position for 1 Year would result in 47.62% of your transactions generating a profit, with an average return of +0.02% per trade.

2 Years

xxx

Success Rate

5/11 ratings generated profit

Average Return

-2.32%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 45.45% of your transactions generating a profit, with an average return of -2.32% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

FDMT Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, FDMT has received 13 Buy Ratings, 11 Hold Ratings, and 2 Sell Ratings. FDMT average Analyst price target in the past 3 months is 26.99.

Each month's total comprises the sum of three months' worth of ratings.

FDMT Financial Forecast

FDMT Earnings Forecast

Next quarter’s earnings estimate for FDMT is -$1.01 with a range of -$1.30 to -$0.80. The previous quarter’s EPS was -$0.98. FDMT beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.19% of the time in the same period. In the last calendar year FDMT has Outperformed its overall industry.

FDMT Sales Forecast

Next quarter’s sales forecast for FDMT is $255.00K with a range of $0.00 to $2.00M. The previous quarter’s sales results were $15.00K. FDMT beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.39% of the time in the same period. In the last calendar year FDMT has Preformed in-line its overall industry.

FDMT Stock Forecast FAQ

What is FDMT’s average 12-month price target, according to analysts?

Based on analyst ratings, 4D Molecular Therapeutics, Inc.’s 12-month average price target is 26.99.

What is FDMT’s upside potential, based on the analysts’ average price target?

4D Molecular Therapeutics, Inc. has 271.76% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is FDMT a Buy, Sell or Hold?

4D Molecular Therapeutics, Inc. has a consensus rating of Moderate Buy which is based on 8 buy ratings, 2 hold ratings and 1 sell ratings.

What is 4D Molecular Therapeutics, Inc.’s price target?

The average price target for 4D Molecular Therapeutics, Inc. is 26.99. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $45.00 ,the lowest forecast is $5.50. The average price target represents 271.76% Increase from the current price of $7.26.

What do analysts say about 4D Molecular Therapeutics, Inc.?

4D Molecular Therapeutics, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of FDMT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

4D Molecular Therapeutics (FDMT) Stock Forecast & Price Target

FDMT Analyst Ratings

FDMT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering 4D Molecular Therapeutics

FDMT Analyst Recommendation Trends

FDMT Financial Forecast

FDMT Earnings Forecast

FDMT Sales Forecast

FDMT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts